Advertisement

Complementary and alternative medicine use in glioma patients in France

  • Emilie Le RhunEmail author
  • Patrick Devos
  • Véronique Bourg
  • Amélie Darlix
  • Véronique Lorgis
  • Guido Ahle
  • Mathieu Boone
  • Luc Taillandier
  • Elsa Curtit
  • Louis Gras
  • Christine Lebrun Frenay
  • Dorothee Gramatzki
  • Carole Ramirez
  • Nicolas Simon
  • Michael Weller
Clinical Study

Abstract

Purpose

Complementary and alternative medicine (CAM) use increases in cancer patients, including adult patients with diffuse gliomas.

Methods

Questionnaires addressing CAM use were distributed to adult patients with gliomas of WHO grades II-IV and ECOG performance score of 0–2 during hospital visits and filled in anonymously. The study was conducted in nine centers in France from May 2017 to May 2018. Descriptive cohort analyses and comparative analyses according to gender, age, WHO grade, and recurrent versus newly diagnosed disease were conducted.

Results

Two hundred twenty-seven questionnaires were collected; 135 patients (59%) were male. Median age was 48 years, 105 patients (46%) declared having glioblastoma, 99 patients (43%) declared having recurrent disease. Hundred-three patients (45%) had modified their alimentary habits after the glioma diagnosis. At the time of the questionnaire, 100 patients (44%) were on complementary treatment, mainly vitamins and food supplements, and 73 patients (32%) used alternative medicine approaches, mainly magnetism and acupuncture. In total, 154 patients (68%) declared using at least one of these approaches. Expenditures exceeding 100 € per month were reported by users in 14% for modification of alimentary habits, in 25% for complementary treatment, and in 18% for alternative medicines. All approaches were commonly considered as improving quality of life and experienced as efficient, notably those associated with more expenditures.

Conclusions

CAM are frequently used by glioma patients in France. Underlying needs and expectations, as well as potential interactions with tumor-specific treatments, and financial and quality of life burden, should be discussed with patients and caregivers.

Keywords

Acupuncture Brain Diet Magnetism Supplements Vitamins 

Notes

Acknowledgements

The authors would like to thank Stéphanie Heudre for excellent administrational support.

Supplementary material

11060_2019_3315_MOESM1_ESM.docx (201 kb)
Electronic supplementary material 1 (DOCX 202 kb)

References

  1. 1.
    Horneber M, Bueschel G, Dennert G et al (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11:187–203.  https://doi.org/10.1177/1534735411423920 CrossRefPubMedGoogle Scholar
  2. 2.
    Wieland LS, Manheimer E, Berman BM (2011) Development and classification of an operational definition of complementary and alternative medicine for the Cochrane collaboration. Altern Ther Health Med 17:50–59PubMedPubMedCentralGoogle Scholar
  3. 3.
    Ostrom QT, Gittleman H, Truitt G, et al (2018) CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-oncology 20:iv1–iv86. https://doi.org/10.1093/neuonc/noy131 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466.  https://doi.org/10.1016/S1470-2045(09)70025-7 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722.  https://doi.org/10.1056/NEJMoa1308345 CrossRefPubMedGoogle Scholar
  6. 6.
    Gilbert MR, Sulman EP, Mehta MP (2014) Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:2048–2049.  https://doi.org/10.1056/NEJMc1403303 CrossRefPubMedGoogle Scholar
  7. 7.
    Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316.  https://doi.org/10.1001/jama.2017.18718 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Weller M, Butowski N, Tran DD et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:1373–1385.  https://doi.org/10.1016/S1470-2045(17)30517-X CrossRefPubMedGoogle Scholar
  9. 9.
    Gramatzki D, Dehler S, Rushing EJ et al (2016) Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer 122:2206–2215.  https://doi.org/10.1002/cncr.30023 CrossRefPubMedGoogle Scholar
  10. 10.
    van den Bent MJ, Brandes AA, Taphoorn MJB et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350.  https://doi.org/10.1200/JCO.2012.43.2229 CrossRefPubMedGoogle Scholar
  11. 11.
    Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343.  https://doi.org/10.1200/JCO.2012.43.2674 CrossRefPubMedGoogle Scholar
  12. 12.
    van den Bent MJ, Baumert B, Erridge SC et al (2017) Interim results from the CATNON trial (EORTC study 26053–22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet.  https://doi.org/10.1016/S0140-6736(17)31442-3 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Buckner JC, Shaw EG, Pugh SL et al (2016) Radiation plus Procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374:1344–1355.  https://doi.org/10.1056/NEJMoa1500925 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mao JJ, Palmer CS, Healy KE et al (2011) Complementary and alternative medicine use among cancer survivors: a population-based study. J Cancer Surviv 5:8–17.  https://doi.org/10.1007/s11764-010-0153-7 CrossRefPubMedGoogle Scholar
  15. 15.
    Firkins R, Eisfeld H, Keinki C et al (2018) The use of complementary and alternative medicine by patients in routine care and the risk of interactions. J Cancer Res Clin Oncol 144:551–557.  https://doi.org/10.1007/s00432-018-2587-7 CrossRefPubMedGoogle Scholar
  16. 16.
    Verhoef MJ, Hagen N, Pelletier G, Forsyth P (1999) Alternative therapy use in neurologic diseases: use in brain tumor patients. Neurology 52:617–622.  https://doi.org/10.1212/wnl.52.3.617 CrossRefPubMedGoogle Scholar
  17. 17.
    Fox S, Laws ER, Anderson F, Farace E (2006) Complementary therapy use and quality of life in persons with high-grade gliomas. J Neurosci Nurs 38:212–220CrossRefGoogle Scholar
  18. 18.
    Armstrong T, Cohen MZ, Hess KR et al (2006) Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J Pain Symptom Manage 32:148–154.  https://doi.org/10.1016/j.jpainsymman.2006.02.015 CrossRefPubMedGoogle Scholar
  19. 19.
    Heese O, Schmidt M, Nickel S et al (2010) Complementary therapy use in patients with glioma: an observational study. Neurology 75:2229–2235.  https://doi.org/10.1212/WNL.0b013e31820202c6 CrossRefPubMedGoogle Scholar
  20. 20.
    Eisele G, Roelcke U, Conen K et al (2019) Complementary and alternative medicine use by glioma patients in Switzerland. Neurooncol Pract 6:237–244.  https://doi.org/10.1093/nop/npy035 CrossRefPubMedGoogle Scholar
  21. 21.
    Mulpur BH, Nabors LB, Thompson RC et al (2015) Complementary therapy and survival in glioblastoma. Neurooncol Pract 2:122–126.  https://doi.org/10.1093/nop/npv008 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    MacLennan AH, Wilson DH, Taylor AW (2002) The escalating cost and prevalence of alternative medicine. Prev Med 35:166–173CrossRefGoogle Scholar
  23. 23.
    Mobed K, Liu R, Stewart S et al (2009) Quality of Life and Patterns of Use of Complementary and Alternative Medicines Among Glioma Patients. J Support Oncol 7:W23–W31PubMedPubMedCentralGoogle Scholar
  24. 24.
    Saper RB, Phillips RS, Sehgal A et al (2008) Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA 300:915–923.  https://doi.org/10.1001/jama.300.8.915 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Markman M (2002) Safety issues in using complementary and alternative medicine. J Clin Oncol 20:39S–41SCrossRefGoogle Scholar
  26. 26.
    Melchart D, Hager S, Albrecht S et al (2017) Herbal Traditional Chinese Medicine and suspected liver injury: A prospective study. World J Hepatol 9:1141–1157.  https://doi.org/10.4254/wjh.v9.i29.1141 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Markowitz JS, Donovan JL, DeVane CL et al (2003) Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290:1500–1504.  https://doi.org/10.1001/jama.290.11.1500 CrossRefPubMedGoogle Scholar
  28. 28.
    Noorlag L, De Vos FY, Kok A et al (2018) Treatment of malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies. Clin Nutr.  https://doi.org/10.1016/j.clnu.2018.10.024 CrossRefPubMedGoogle Scholar
  29. 29.
    Klement RJ, Bandyopadhyay PS, Champ CE, Walach H (2018) Application of Bayesian evidence synthesis to modelling the effect of ketogenic therapy on survival of high grade glioma patients. Theor Biol Med Model 15:12.  https://doi.org/10.1186/s12976-018-0084-y CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Rieger J, Bähr O, Maurer GD et al (2014) ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol 44:1843–1852.  https://doi.org/10.3892/ijo.2014.2382 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Tasaki K, Maskarinec G, Shumay DM et al (2002) Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients’ perspectives. Psychooncology 11:212–220.  https://doi.org/10.1002/pon.552 CrossRefPubMedGoogle Scholar
  32. 32.
    Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26:665–673.  https://doi.org/10.1200/JCO.2007.13.5905 CrossRefPubMedGoogle Scholar
  33. 33.
    Davis EL, Oh B, Butow PN et al (2012) Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. Oncologist 17:1475–1481.  https://doi.org/10.1634/theoncologist.2012-0223 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Richardson J (2004) What patients expect from complementary therapy: a qualitative study. Am J Public Health 94:1049–1053.  https://doi.org/10.2105/ajph.94.6.1049 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Stub T, Quandt SA, Arcury TA et al (2016) Perception of risk and communication among conventional and complementary health care providers involving cancer patients’ use of complementary therapies: a literature review. BMC Complement Altern Med 16:353.  https://doi.org/10.1186/s12906-016-1326-3 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Stan DL, Wahner-Roedler DL, Yost KJ et al (2018) Absent and Discordant Electronic Health Record Documentation of Complementary and Alternative Medicine in Cancer Care. J Altern Complement Med 24:988–995.  https://doi.org/10.1089/acm.2018.0141 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Emilie Le Rhun
    • 1
    • 2
    • 3
    • 14
    Email author
  • Patrick Devos
    • 4
  • Véronique Bourg
    • 5
  • Amélie Darlix
    • 6
  • Véronique Lorgis
    • 7
  • Guido Ahle
    • 8
  • Mathieu Boone
    • 9
  • Luc Taillandier
    • 10
  • Elsa Curtit
    • 11
  • Louis Gras
    • 12
  • Christine Lebrun Frenay
    • 5
  • Dorothee Gramatzki
    • 3
  • Carole Ramirez
    • 2
  • Nicolas Simon
    • 13
  • Michael Weller
    • 3
  1. 1.Univ. Lille, U1192 - PRISMLilleFrance
  2. 2.CHU Lille, Neuro-oncology, General and Stereotaxic Neurosurgery DepartmentLilleFrance
  3. 3.Department of NeurologyUniversity Hospital and University of Zurich, Frauenklinikstrasse 26ZurichSwitzerland
  4. 4.Univ. Lille, CHU Lille, EA 2694 - Santé Publique: Épidémiologie et Qualité des SoinsLilleFrance
  5. 5.Department of Neurology, Pasteur2 HospitalNice Côte D’Azur UniversityNiceFrance
  6. 6.Department of Medical Oncology, Institut du Cancer de MontpellierUniversity of MontpellierMontpellierFrance
  7. 7.Georges François LeclercDijonFrance
  8. 8.Department of Neurology, Hôpitaux CivilsColmarFrance
  9. 9.Department of Medical Oncology, CHUAmiensFrance
  10. 10.University HospitalNancyFrance
  11. 11.University HospitalBesançonFrance
  12. 12.Centre Léonard de VinciDechyFrance
  13. 13.Univ. Lille, CHU Lille, EA 7365 – GRITA – Groupe de Recherche sur les Formes Injectables et les Technologies AssociéesLilleFrance
  14. 14.Neuro-Oncology, Neurosurgery Department, Roger Salengro Hospital, Rue Emile LaineUniversity Hospital CHRULille CedexFrance

Personalised recommendations